Immatics N.V. $IMTX Stock Sold by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. lessened its stake in Immatics N.V. (NASDAQ:IMTX) by 1.3% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 6,422,780 shares of the company’s stock after selling 84,022 shares during the period. Immatics comprises approximately 0.4% of Jefferies Financial Group Inc.’s portfolio, making the stock its 28th largest position. Jefferies Financial Group Inc. owned 4.70% of Immatics worth $56,392,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in IMTX. Tidal Investments LLC lifted its stake in Immatics by 0.7% during the second quarter. Tidal Investments LLC now owns 171,499 shares of the company’s stock worth $1,737,000 after purchasing an additional 1,110 shares in the last quarter. Engineers Gate Manager LP grew its stake in shares of Immatics by 26.4% in the second quarter. Engineers Gate Manager LP now owns 50,886 shares of the company’s stock valued at $515,000 after buying an additional 10,638 shares in the last quarter. Bank of America Corp DE grew its stake in shares of Immatics by 87.5% in the first quarter. Bank of America Corp DE now owns 25,394 shares of the company’s stock valued at $250,000 after buying an additional 11,848 shares in the last quarter. Doliver Advisors LP acquired a new stake in shares of Immatics in the third quarter valued at $263,000. Finally, SummitTX Capital L.P. raised its holdings in shares of Immatics by 56.1% in the 1st quarter. SummitTX Capital L.P. now owns 151,112 shares of the company’s stock valued at $1,487,000 after buying an additional 54,328 shares during the period. Institutional investors and hedge funds own 64.41% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on IMTX. Wall Street Zen downgraded Immatics from a “hold” rating to a “sell” rating in a research report on Saturday, October 31st. Jefferies Financial Group set a $17.00 price target on shares of Immatics in a research report on Tuesday, August 25th. Stifel Nicolaus initiated coverage on shares of Immatics in a report on Tuesday, October 13th. They issued a “buy” rating and a $15.00 price objective for the company. Mizuho set a $21.00 price objective on shares of Immatics in a report on Thursday, October 29th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immatics in a research note on Friday, September 18th. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $19.00.

Insiders Place Their Bets

In other Immatics news, Director Perceptive Advisors Llc purchased 863,060 shares of the business’s stock in a transaction on Wednesday, August 26th. The shares were bought at an average cost of $8.69 per share, for a total transaction of $7,499,991.40. Following the completion of the purchase, the director directly owned 11,246,516 shares in the company, valued at approximately $97,732,224.04. This represents a 8.31% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 3.30% of the stock is currently owned by corporate insiders.

Immatics Stock Up 4.2%

Shares of Immatics stock opened at $6.69 on Thursday. Immatics N.V. has a 52-week low of $6.09 and a 52-week high of $12.41. The company has a market capitalization of $914.46 million, a P/E ratio of -3.43 and a beta of 1.38. The company has a 50 day moving average of $7.83 and a 200 day moving average of $9.45.

Immatics (NASDAQ:IMTX) last announced its quarterly earnings data on Tuesday, November 10th. The company reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.07). The firm had revenue of $7.84 million during the quarter, compared to analysts’ expectations of $12.18 million. Immatics had a negative net margin of 533.26% and a negative return on equity of 52.27%. As a group, research analysts anticipate that Immatics N.V. will post -1.99 earnings per share for the current fiscal year.

About Immatics

Immatics is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer. Founded in Germany in 2000, the company uses its target-discovery and development platforms to identify cancer-associated targets and create therapies designed to direct the immune system against tumor cells. Its pipeline includes engineered T-cell receptor (TCR) T-cell therapies, which modify a patient’s T cells to recognize specific tumor targets, as well as TCR bispecific therapies designed to connect T cells with cancer cells.